Overview

With doxy-PEP, gonorrhoea prevention is especially sensitive to the tetracycline susceptibility of circulating Neisseria gonorrhoeae. Local resistance can change the expected benefit of the same 200 mg post-exposure regimen, helping explain why trials show a smaller and less uniform effect than for syphilis and chlamydia. The evidence does not provide a universal resistance cutoff or prove that resistance explains every difference. Repeated antibiotic exposure may also select for resistance in gonorrhoea, other pathogens or the microbiome, while small follow-up datasets give signals rather than final forecasts. Tracking STI incidence, resistance and antibiotic use makes this changing benefit–harm relationship visible.

Learning outcomes

Local tetracycline resistance can materially change gonorrhoea benefit without changing the doxy-PEP dose.
AMR signals from small, selected datasets are reasons for monitoring, not proof of inevitable resistance or collapse.
Surveillance should pair STI incidence with resistance and antibiotic-use trends so programs can reassess changing value.

Keywords

Doxy-PEPgonorrhoearesistancesusceptibilitysurveillancemicrobiome

Why Gonorrhoea Is the Unsettled Case: Resistance, Place and Feedback

The gonorrhoea branch of doxy-PEP is where a promising prevention result becomes a local biological question. The focus here is not whether doxycycline can ever reduce gonorrhoea, but why its effect depends more heavily on the tetracycline susceptibility of circulating Neisseria gonorrhoeae than the stronger syphilis and chlamydia signals suggest. Understanding that relationship lets readers distinguish a genuine setting constraint from random trial noise—and see why antimicrobial-resistance surveillance belongs inside the intervention.

Why gonorrhoea changes the meaning of success

Doxy-PEP is one regimen, but the bacterial target is not one uniform population. For gonorrhoea, WHO identifies the prevalence of circulating tetracycline resistance as a key determinant of the preventive effect. In plain terms, the proportion of local gonococcal strains that remain sufficiently susceptible can change how much protection a 200 mg post-exposure dose is able to provide. A result measured in one bacterial environment is therefore not a portable guarantee for every other environment.

This relationship gives a biological explanation for the trial pattern. In the IPERGAY substudy, the gonorrhoea difference was not statistically significant, even though chlamydia and syphilis fell substantially. In the U.S. DoxyPEP trial, gonorrhoea incidence was reduced among both the group taking HIV PrEP and the group living with HIV, with relative risks of 0.45 and 0.43. In the French DOXYVAC trial, the adjusted hazard ratio for gonorrhoea was 0.49. The studies point in a broadly favorable direction overall, but the magnitude is smaller and less uniform than for the other two infections.

The important inference is not that the first trial “got gonorrhoea wrong” and the later trials “got it right.” The evidence is better read as a signal that the gonorrhoea outcome is sensitive to conditions that differ across studies. Local resistance is one such condition, and WHO names it explicitly. Participant characteristics, exposure networks, adherence, outcome measurement and statistical precision can also contribute. Resistance is the clearest pathogen-level explanation in the available guidance, but it is not a license to explain every difference with resistance alone.

The distinction between prevention and treatment makes the same point from another angle. CDC notes that doxycycline is not currently a recommended treatment for gonorrhoea because of elevated antimicrobial resistance, although it remains effective against many strains in the United States. A medicine can retain a useful preventive effect in a population while being unsuitable as the routine treatment for an established infection. Prevention and treatment ask different questions, involve different timing and may face different susceptibility requirements. Doxy-PEP should not be interpreted as a replacement for testing and appropriate treatment.

Nor does “resistance” mean that every gonococcal strain in a setting is resistant. It is a population-level property that can vary in prevalence. If a local bacterial population contains more strains against which doxycycline is less effective, the average preventive effect can be lower even when some exposures still involve susceptible strains. This is why the guideline speaks about circulating resistance and setting-specific effectiveness rather than offering a universal yes-or-no label for gonorrhoea.

The absence of a universal cutoff is itself important.

Published by DeepMox

FAQ

Why does local resistance matter for doxy-PEP and gonorrhoea?

A higher share of less-susceptible local strains can lower the average preventive effect of the same 200 mg dose. The evidence does not provide a universal resistance prevalence at which doxy-PEP stops working.

Does doxy-PEP definitely cause antimicrobial resistance?

No. Current evidence is limited and uncertain, while WHO identifies possible selection for tetracycline resistance in gonorrhoea, other pathogens and the microbiome. Small follow-up signals do not prove the same outcome everywhere.

What should doxy-PEP resistance surveillance measure?

It should track resistance and antibiotic use alongside STI incidence, preserving denominators and sample sizes over time. User, service and, where feasible, microbiome data can add context for reassessment.

Previous10 minDoxy-PEP: Four Gates to Protection

Next9 minDoxy-PEP Evidence Across Populations

Doxy-PEP and Gonorrhoea Resistance

Why Gonorrhoea Is the Unsettled Case: Resistance, Place and Feedback

Why gonorrhoea changes the meaning of success

FAQ